Biogen company information, Employees & Contact Information

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA Biogen

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia Biogen

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission Biogen

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer’s Disease Biogen

Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia Biogen

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Biogen

Biogen (BIIB): Company Profile, Stock Price, News, Rankings Fortune

After years of sales declines, 'a new Biogen' emerges as launches take flight: CEO Fierce Pharma

Company Biogen

Mission and Culture Biogen

Learning and Leading: Lauren Love’s Co-op Experience Biogen

CoLab | Community Lab Biogen

Biogen Foundation Biogen

Kylie Bromley - Biogen - Board Member Association of the British Pharmaceutical Industry (ABPI)

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments Biogen

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences Biogen

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025 Biogen

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China Biogen

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen Biogen

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square Biogen

Biogen to Realign Resources for Alzheimer's Disease Franchise Biogen

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union Biogen

Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia Biogen

Leqembi® (lecanemab) Authorized for Early Alzheimer’s Disease in Great Britain Biogen

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union Biogen

Benefits Biogen

Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments Biogen

Biogen to Acquire Reata Pharmaceuticals Biogen

Capability Center India | Biogen Biogen

Mamelodi Sundowns and Biogen forge partnership in pursuit of excellence Mamelodi Sundowns | Official Website

Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status Biogen

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease Biogen

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA Biogen

“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in the United Arab Emirates Biogen

Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab Biogen

“LEQEMBI®” (Lecanemab) Approved for the Treatment of Early Alzheimer’s Disease in Mexico Biogen

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP Biogen

Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an Industry Record 5th Time; Recognition Reflects Longstanding ESG Leadership Biogen

Biogen groundbreaking stirs optimism in Kendall Square MIT News

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in South Korea Biogen

FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease Biogen

LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EA Biogen

Mamelodi Sundowns Secure Premium Wellness Partnership With Biogen to Elevate Player Nutrition and Recovery Central News South Africa

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders Biogen

Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases Biogen

Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer’s Disease At Clinical Trials On Alzheimer’s Disease (Ctad) Conference Biogen

FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease Biogen

Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People wit Biogen

Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting Biogen

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China Biogen

Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience Biogen

Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies Biogen

Biogen (NASDAQ:BIIB) Reports Bullish Q2 Yahoo Finance

“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in South Korea Biogen

How a Premier U.S. Drug Company Became a Virus ‘Super Spreader’ (Published 2020) The New York Times

Biogen Announces Agreement to Acquire Nightstar Therapeutics to Establish Clinical Pipeline of Gene Therapy Candidates in Ophthalmology Biogen

Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index Biogen

Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company Biogen

Eisai, Biogen's Leqembi nabs UK nod, but reimbursement remains elusive Fierce Pharma

BIOGEN IDEC AND SANGAMO BIOSCIENCES ANNOUNCE GLOBAL COLLABORATION TO DEVELOP TREATMENTS FOR HEMOGLOBINOPATHIES Biogen

Biogen makes a billion-dollar bet on Parkinson’s drugs BioPharma Dive

Biogen Energy, Oil & Gas magazine

Biogen Stock Is Facing A Crucial Test — Here's What You Need To Know Investor's Business Daily

Biogen Idec Celebrates 30 Years of Transforming Discovery into Care Biogen

#Campaigns: Turning Hobbo's life around with #BiogenJourney • MarkLives.com

Biogen product found to contain ‘roids’ TimesLIVE